- Home
- IHRT vs TNGX Comparison
IHRT vs TNGX Comparison
Compare IHRT & TNGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IHRT
- TNGX
- Stock Information
- Founded
- IHRT 1974
- TNGX 2014
- Country
- IHRT United States
- TNGX United States
- Employees
- IHRT N/A
- TNGX N/A
- Industry
- IHRT Broadcasting
- TNGX Biotechnology: Pharmaceutical Preparations
- Sector
- IHRT Consumer Discretionary
- TNGX Health Care
- Exchange
- IHRT Nasdaq
- TNGX Nasdaq
- Market Cap
- IHRT N/A
- TNGX 317.4M
- IPO Year
- IHRT 2019
- TNGX N/A
- Fundamental
- Price
- IHRT $1.21
- TNGX $1.10
- Analyst Decision
- IHRT Buy
- TNGX Strong Buy
- Analyst Count
- IHRT 3
- TNGX 7
- Target Price
- IHRT $2.83
- TNGX $12.33
- AVG Volume (30 Days)
- IHRT 598.4K
- TNGX 542.7K
- Earning Date
- IHRT 05-12-2025
- TNGX 05-12-2025
- Dividend Yield
- IHRT N/A
- TNGX N/A
- EPS Growth
- IHRT N/A
- TNGX N/A
- EPS
- IHRT N/A
- TNGX N/A
- Revenue
- IHRT $3,854,532,000.00
- TNGX $42,069,000.00
- Revenue This Year
- IHRT $0.97
- TNGX N/A
- Revenue Next Year
- IHRT $5.09
- TNGX N/A
- P/E Ratio
- IHRT N/A
- TNGX N/A
- Revenue Growth
- IHRT 2.76
- TNGX 15.17
- 52 Week Low
- IHRT $0.81
- TNGX $1.11
- 52 Week High
- IHRT $2.84
- TNGX $12.02
- Technical
- Relative Strength Index (RSI)
- IHRT 51.94
- TNGX 33.44
- Support Level
- IHRT $1.02
- TNGX $1.38
- Resistance Level
- IHRT $1.09
- TNGX $1.56
- Average True Range (ATR)
- IHRT 0.08
- TNGX 0.16
- MACD
- IHRT 0.04
- TNGX -0.01
- Stochastic Oscillator
- IHRT 86.67
- TNGX 9.90
About TNGX Tango Therapeutics Inc.
Tango Therapeutics Inc is a biotechnology company. It is dedicated towards discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. Its program TNG908, is an MTA-cooperative inhibitor of PRMT5 designed to work selectively in cancer cells with an MTAP deletion. Its pipeline further consists of discovery programs such as, TNG462, TNG348, TNG260 and others for multiple cancer types with limited treatment options.